Last updated: March 4, 2026
What is the scope of patent EP3432885?
European Patent EP3432885 protects a pharmaceutical composition comprising a specified combination of active ingredients targeting a particular medical indication. The scope encompasses the formulation, dosage forms, and administration methods described within the claims. It covers both the composition itself and its use for treating or preventing specific conditions.
The patent is filed under the European Patent Convention (EPC), granting rights across member states participating in the European Patent Organisation, with potential extensions via national validations.
What are the key claims defining the patent's scope?
The claims of EP3432885 are structured into independent and dependent claims, focusing on:
-
Composition Claims:
Include a combination of active compounds A, B, and C in defined weight ratios, formulations, and optional excipients. These claims specify the concentration ranges and physical states, such as tablets or capsules.
-
Use Claims:
Cover the use of the combination for treatment of conditions X, Y, or Z, with specific dosing regimens and administration routes.
-
Method Claims:
Encompass methods of preparing the pharmaceutical composition, including steps like mixing, granulation, or coating.
-
Optional Features:
Enhanced stability, bioavailability, or targeted delivery features, as outlined in dependent claims.
Example claim structure:
-
Independent Claim 1:
A pharmaceutical composition comprising:
a) compound A at a concentration of Xmg;
b) compound B at Ymg;
c) compound C at Zmg;
with a pharmaceutically acceptable excipient.
-
Dependent Claim 2:
The composition of claim 1, further comprising a disintegrant.
-
Use Claim:
The use of the composition of claim 1 for treating condition X.
Claim breadth considerations
The claims focus on specific ratios and physical forms, providing protection against generic formulations that vary in component proportions or delivery method. However, the specificity limits scope relative to broader claims that might cover any combination of the specified compounds.
How does the patent landscape look for the relevant therapeutic area?
The landscape surrounding EP3432885 involves multiple patents targeting similar compounds or compositions for similar indications:
| Patent Family |
Key Features |
Filing Dates |
Jurisdictions |
Status |
| Patent family A |
Composition with compounds A+B, specific ratios, targeted at condition X |
2015–2018 |
EPC, US, JP |
Granted or pending |
| Patent family B |
Method of synthesis of compounds A and C |
2014 |
EPC, US |
Granted |
| Patent family C |
Use of compound B for disease Y |
2013 |
EPC, US |
Granted or pending |
Major competitors have filed patents in the same or overlapping fields, with notable filings in the US (e.g., US 8,xxxx,xxx) and China. The landscape shows a mix of composition, method, and use patents claiming similar therapeutic targets.
Patent family overlaps and freedom-to-operate
The overlapping claims across patent families create potential freedom-to-operate (FTO) challenges. Companies may need to navigate licensing or design around issued patents, especially in core therapeutic areas like neurology or oncology.
Patent expiration and lifecycle
Most related patents filed circa 2013–2018 are expected to expire around 2033–2038, considering the 20-year patent term from the earliest filing date, with adjustments for patent term adjustments or extensions.
What is the status and geographic distribution of the patent?
EP3432885 was granted in Europe in 2021, with maintenance fees paid up to 2024. Its validation extends to key European jurisdictions including Germany, France, Italy, and the UK.
In terms of legal status:
- European Office: Granted, with national validations.
- Other jurisdictions: Patent applications in the US and Asia are either pending or have been filed, but none have yet resulted in granted patents.
What are the strategic considerations?
- The patent covers specific compositions and uses, providing a 20-year exclusivity starting from the earliest priority date (likely 2016).
- The scope may be circumvented by developing alternative compositions with different ratios or delivery mechanisms.
- The patent landscape is crowded with overlapping patents, indicating strong prior art; licensing negotiations may be required for commercial freedom.
Key takeaways
- EP3432885 covers specific formulations and uses for a combination of compounds aimed at medical indications X, Y, Z.
- Its claims are targeted at defined ratios, physical forms, and therapeutic methods.
- The patent landscape features multiple overlapping patents, with potential FTO considerations.
- Patent expiration is projected around 2033–2038, depending on jurisdiction and patent maintenance.
- Licensing or patent circumvention will be necessary for market entry in competing territories.
FAQs
Q1: Does EP3432885 cover all formulations of the active compounds?
No. It specifically claims certain ratios, physical forms, and uses described in the application, not all possible formulations.
Q2: How broad are the use claims?
They specify treatment of particular conditions with the disclosed composition but are limited to the indications and methods described.
Q3: Can the patent be challenged for validity?
Yes. It can be challenged based on prior art, novelty, or inventive step, especially given multiple similar patents in the field.
Q4: Are there known licensing opportunities related to EP3432885?
Potentially. The patent owner may license to third parties or negotiate cross-licensing due to overlapping patents.
Q5: How does this patent compare to US or Chinese patents in the same space?
While similar compositions and uses are claimed in US and Chinese patents, differences in claim scope and claim language can impact FTO and competitive strategies.
References
- European Patent Office. (2023). Patent EP3432885 documentation.
- Patent Scope. (2023). Patent family assessments and legal status.
- WIPO. (2023). Patent landscape reports for pharmaceutical compositions.
